Eli Lilly reported record earnings in the first quarter of 2026, driven by strong overseas sales of Mounjaro (a GLP-1 diabetes and weight-loss drug). The company is now focused on launching Foundayo, its new pill form of the drug, which the FDA approved in April, and says 80% of early prescriptions are going to patients trying GLP-1 drugs for the first time.

• •Q1 2026 revenue rose 56% to $19.8B, beating estimates by $2B+
• •Mounjaro/Zepbound sales more than doubled to $8.7B
• •Lilly holds 60%+ US GLP-1 share vs Novo's 39.4%

Eli Lilly reported strong first-quarter 2026 earnings, with total revenue jumping 56% to $19.8 billion, driven largely by higher sales volume of its diabetes and weight-loss drugs Mounjaro and Zepbound. However, the company earned less money per dose sold due to lower prices for those two medicines.

• •Q1 2026 total revenue rose 56% to $19.8 billion
• •Growth driven by higher Mounjaro and Zepbound sales volume
• •Realized price per dose declined for both drugs